Movember is excited to announce that, thanks to our Mo Bros and Mo Sistas, a donation of $7.7 million has been made to our men’s health partner, the Prostate Cancer Foundation. The might of the Mo is growing each year funding collaborative, innovative prostate cancer research. By foregoing your razors for the 30 days of Movember, Mo Bros (with the critical support of Mo Sistas) are changing the face of men’s health, and moving us to the day where men will be treated with individualized precision therapy – no longer dying from prostate cancer.
Stay tuned, as we will continue to announce new Movember funded programs.
“PROSTATE CANCER FOUNDATION ANNOUNCES
$7.7 MILLION MOVEMBER GRANT TO ADVANCE
PROSTATE CANCER RESEARCH
SANTA MONICA, CA, May 30, 2013 —– The Prostate Cancer Foundation (PCF) has received $7.7 million from their partner Movember, the global men’s health charity that gets men to grow and women to support the moustache for thirty days each November to raise funds and awareness for cancers affecting men. The PCF will allocate the $7.7 million to find better treatments and ultimately a cure, by funding accelerated research.
To date, Movember has donated more than $18 million to PCF to support prostate cancer research, funding nine game-changing PCF Research Enterprise awards in the U.S. and Great Britain. The data generated from these Movember-funded projects has changed the daily practice of oncology for every patient with advanced prostate cancer in the Western World.
Movember-supported projects through PCF have ranged from prostate cancer research in clinical trials that helped accelerate the approval of two new drugs, Abiraterone and Enzalutamide, both used to treat metastatic castration-resistant prostate cancer; to a Movember Challenge Award at the University of Michigan led by Drs. Arul Chinnaiyan and Ken Pienta. This Movember Challenge Award created the world’s first integrated precision medicine program to perform genomic analysis from patient biopsies. These results are discussed in a panel of multidisciplinary professionals including oncologists, bioethicists, pharmacologists and genetic counselors and customized therapy is suggested.
The SU2C-PCF Prostate Dream Team Translational Cancer Research Grant, funded in conjunction with Movember, will provide up to $10 million over three years working to identify the causes of resistance in an individual patient and help doctors tailor therapy for them. Movember will fund $2.5 million of the Dream Team, along with $2.5 million from SU2C, and $5 million from PCF. This collaborative award will represent six world-class institutions; four campuses of the University of California (San Francisco, Los Angeles, Santa Cruz, Davis), Oregon Health & Science University in Portland, and the University of British Columbia in Vancouver, Canada.
“We are grateful to be partnered with Movember. What started out as a quirky idea among friends has turned into a global phenomenon,” said Jonathan W. Simons, MD, president and CEO of PCF. “No other organization in history has been this successful in moving the awareness needle and bringing in more dollars to support much needed research for prostate cancer and men’s health. The power of the Mo is encouraging discussion and saving lives.”
PCF looks forward to providing updates on this life-saving research and announcing several new Movember-PCF Challenge Awards in the next few months.
